Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 8/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31373313 | 1.00 | CCR4 (0.33) | CCR4POLBTDP1ALDH1A1CYP1A2 | |
| SCHEMBL5839510 | 0.80 | POLB (0.50) | POLBTDP1ALDH1A1CYP1A2 | |
| SCHEMBL19715581 | 0.77 | NQO2 (0.37) | CCR4POLBTDP1ALDH1A1CYP1A2 | |
| SCHEMBL31546798 | 0.76 | RECQL (0.36) | CCR4POLBTDP1ALDH1A1CYP1A2 | |
| SCHEMBL22168317 | 0.76 | APOBEC3A (0.40) | ALDH1A1CYP1A2CYP2C19CCR5 | |
| SCHEMBL14971502 | 0.76 | NQO2 (0.40) | CCR4POLBTDP1ALDH1A1 | |
| SCHEMBL2416576 | 0.74 | CCR4 (0.41) | CCR4POLBTDP1ALDH1A1CCR5 | |
| SCHEMBL22257074 | 0.74 | POLB (0.36) | CCR4POLBTDP1ALDH1A1CYP1A2 | |
| SCHEMBL17477974 | 0.74 | CRHBP (0.41) | CCR4ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31651631 | 0.74 | IDO1 (0.35) | CCR4POLBTDP1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746972-A1 | DEUTERATED PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4709381-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2026-03-18 | — | — | EP | disclosed |
| EP-4703362-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | Chengdu Sibeibo Pharmaceutical Technology Co., Ltd (CN) | 2026-03-04 | — | — | EP | disclosed |
| WO-2025061141-A1 | PHARMACEUTICAL COMPOSITION HAVING IMPROVED PHARMACOKINETIC PROPERTIES | 成都思倍博医药科技有限公司 | 2025-03-27 | — | — | WO | disclosed |
| WO-2025031750-A1 | DEUTERATED PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024256377-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024222889-A1 | COMPOUND CONTAINING OXO-PYRIDO-ALIPHATIC RING OR ALIPHATIC HETEROCYCLIC STRUCTURE, AND MEDICAL USE THEREOF | 成都思倍博医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-20220339144-A1 | PYRIDINYL INDOLE COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS CANADA, INC. (CA) | 2022-10-27 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| CN-102884047-A | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO LTD | 2013-01-16 | — | — | CN | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | CCR4 825/4885POLB 4366/4885TDP1 4674/4885 |
| US-20220339144-A1 | PYRIDINYL INDOLE COMPOUNDS AND METHODS OF USE THEREOF | PRKAG3, PRKAG1, PRKAA1 | CCR4 4378/4885POLB 1873/4885TDP1 1579/4885 |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | PDXK, HK1, KCNJ2 | CCR4 4291/4885POLB 2059/4885TDP1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.